{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:02:04Z","timestamp":1791090124447,"version":"4.1.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41433-026-04601-2","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:15:55Z","timestamp":1780712155000},"page":"1423-1424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Defining failure is not enough"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5894-5427","authenticated-orcid":false,"given":"Mark H.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"4601_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.oret.2025.10.006","volume":"10","author":"G Broadhead","year":"2026","unstructured":"Broadhead G, Phan L, Keenan, T, Hong T, Chew E, Chang, A. Defining failure in neovascular age-related macular degeneration. Ophthalmol Retin. 2026;10:250\u201364.","journal-title":"Ophthalmol Retin"},{"key":"4601_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","volume":"127","author":"J L\u00f6tvall","year":"2011","unstructured":"L\u00f6tvall J, Akdis C, Bacharier L, Bjermer L, Casale T, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma Syndrome. J Allergy Clin Immunol. 2011;127:355\u201360.","journal-title":"J Allergy Clin Immunol"},{"key":"4601_CR3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"J Heier","year":"2022","unstructured":"Heier J, Khanani A, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of Intravitreal Faricimab in nAMD (TENAYA and LUCERNE). Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"4601_CR4","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"A Joussen","year":"2021","unstructured":"Joussen A, Ricci F, Paris L, Korn C, Quezada Ruiz C, Zarbin M. Angiopoietin\/Tie2 signaling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35:1305\u201316.","journal-title":"Eye"},{"key":"4601_CR5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"T Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K. Comparison of Ranibizumab with or without Verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138:935\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"4601_CR6","doi-asserted-by":"publisher","first-page":"18751","DOI":"10.1073\/pnas.0905010106","volume":"106","author":"M Saint-Geniez","year":"2009","unstructured":"Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado A, D\u2019Amore P. An essential role for RPE-derived soluble VEGF in the maintenance of the Choriocapillaris. Proc Natl Acad Sci USA. 2009;106:18751\u20136.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04601-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:21:42Z","timestamp":1783434102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04601-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":6,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4601"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04601-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Nelson reports a provisional patent application related to the Mechanism-Matched Endotype (MME) framework and serves as CEO of Retinanet, a consulting entity. No other competing interests are declared.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}